Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.605 AUD | -0.82% | -4.62% | +15.89% |
May. 15 | Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial | MT |
May. 10 | Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 12-04-30 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Thomas Jarrett
COO | Chief Operating Officer | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 12-09-30 |
Justin Ward
BRD | Director/Board Member | - | 15-12-31 |
Director/Board Member | - | 17-11-28 | |
Daniel Astudillo
SAM | Sales & Marketing | - | 18-03-31 |
Maggie Niewidok
SEC | Corporate Secretary | - | 22-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Prendergast
CHM | Chairman | 70 | 18-04-23 |
Alan Dunton
BRD | Director/Board Member | 70 | 20-07-13 |
Director/Board Member | - | 17-11-28 | |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 12-09-30 |
James Graham
CEO | Chief Executive Officer | - | 12-04-30 |
Justin Ward
BRD | Director/Board Member | - | 15-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 203,701,863 | 125,456,123 ( 61.59 %) | 0 | 61.59 % |
Company contact information
Recce Pharmaceuticals Ltd.
Salesforce Tower 180 George Street
2000, Sydney
+61 2 9256 2505
http://www.recce.com.auSector
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.89% | 83.75M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- RCE Stock
- Company Recce Pharmaceuticals Ltd